Matches in Wikidata for { <http://www.wikidata.org/entity/Q61969843> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- Q61969843 description "clinical trial" @default.
- Q61969843 description "ensayo clínico" @default.
- Q61969843 description "ensayu clínicu" @default.
- Q61969843 description "klinisch onderzoek" @default.
- Q61969843 description "клінічне випробування" @default.
- Q61969843 description "临床试验" @default.
- Q61969843 name "Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA" @default.
- Q61969843 type Item @default.
- Q61969843 label "Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA" @default.
- Q61969843 prefLabel "Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA" @default.
- Q61969843 P1050 Q61969843-5F538583-2F36-456E-899C-FC92E0F2742F @default.
- Q61969843 P1132 Q61969843-32B2FAEC-1C2E-4A3C-BA60-5F0E536871E2 @default.
- Q61969843 P1476 Q61969843-7EA94288-BAA2-4C5D-97C4-7A4C0DFEAA82 @default.
- Q61969843 P17 Q61969843-6DD20D93-5507-4C9D-8AB7-3EF88C8AFECF @default.
- Q61969843 P1813 Q61969843-EF333E20-AC9F-47DD-B17F-FF190D7924FE @default.
- Q61969843 P2899 Q61969843-092B8961-0A7A-49C4-8CF6-254A73324587 @default.
- Q61969843 P3098 Q61969843-3C14879C-BFB6-4BD6-9FBA-100D983AFECC @default.
- Q61969843 P31 Q61969843-966065A3-493D-49AF-923D-D82F7C1EDB66 @default.
- Q61969843 P4844 Q61969843-45E1C6B4-CDBF-48C1-8D8A-A54314B7E587 @default.
- Q61969843 P4844 Q61969843-7277FBD0-46A7-4FF1-BF8A-025F965EB1BB @default.
- Q61969843 P580 Q61969843-12528B05-3037-4ECE-9E63-492A90271739 @default.
- Q61969843 P582 Q61969843-6D918BE0-440B-46C9-B671-B722465080EC @default.
- Q61969843 P6099 Q61969843-9D3E9621-96A5-4FE8-A416-BB29AFA9F2B0 @default.
- Q61969843 P6153 Q61969843-19CD81B1-2D31-4992-AAB7-8F2914369808 @default.
- Q61969843 P6153 Q61969843-251FB4EB-9682-4C29-A8E4-6236C2DD32BF @default.
- Q61969843 P6153 Q61969843-313C42B7-B282-4CA2-B980-B8D6E1C2E767 @default.
- Q61969843 P6153 Q61969843-3D002809-C972-45C1-B9FD-1BDEFD4C5EC2 @default.
- Q61969843 P6153 Q61969843-4B12FD39-1BD5-4EDA-95A1-71C0BCF81366 @default.
- Q61969843 P6153 Q61969843-6C588F44-5895-4195-B0FC-77F8D2467636 @default.
- Q61969843 P6153 Q61969843-6D7410E1-33D8-4D49-B161-EDD97C483B78 @default.
- Q61969843 P6153 Q61969843-AC71644A-31AD-489B-9B4B-C4929B8C54FC @default.
- Q61969843 P8005 Q61969843-3F0364D8-032A-42CB-A340-B0D2E08DABB5 @default.
- Q61969843 P8363 Q61969843-87995D54-BC2A-414D-8F54-6303757720F3 @default.
- Q61969843 P1050 Q179630 @default.
- Q61969843 P1132 "+45" @default.
- Q61969843 P1476 "A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone" @default.
- Q61969843 P17 Q30 @default.
- Q61969843 P1813 "MEI-005" @default.
- Q61969843 P2899 "+18" @default.
- Q61969843 P3098 "NCT01993641" @default.
- Q61969843 P31 Q30612 @default.
- Q61969843 P4844 Q1181878 @default.
- Q61969843 P4844 Q416451 @default.
- Q61969843 P580 "2013-12-01T00:00:00Z" @default.
- Q61969843 P582 "2015-05-01T00:00:00Z" @default.
- Q61969843 P6099 Q42824440 @default.
- Q61969843 P6153 Q1360303 @default.
- Q61969843 P6153 Q2725999 @default.
- Q61969843 P6153 Q309350 @default.
- Q61969843 P6153 Q4117596 @default.
- Q61969843 P6153 Q43896855 @default.
- Q61969843 P6153 Q49112 @default.
- Q61969843 P6153 Q5637237 @default.
- Q61969843 P6153 Q640652 @default.
- Q61969843 P8005 Q76651189 @default.
- Q61969843 P8363 Q78089383 @default.